Oral Nanoparticles of SNX10-shRNA Plasmids Ameliorate Mouse Colitis

References

• Molodecky NA, Soon IS, Rabi DM, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142(1):46–54 e42; quiz e30. doi:10.1053/j.gastro.2011.10.001
   PubMed Web of Science ®Google Scholar
• Gong W, Lv N, Wang B, et al. Risk of ulcerative colitis-associated colorectal cancer in China: a multi-center retrospective study. Dig Dis Sci. 2012;57(2):503–507. doi:10.1007/s10620-011-1890-9
   PubMedGoogle Scholar
• Burton PR, Clayton DG, Cardon LR; Wellcome Trust Case Control, C.; Australo-Anglo-American Spondylitis, C. Association scan of 14,500 nonsynonymous SNPs in four diseases identifies autoimmunity variants. Nat Genet. 2007;39(11):1329–1337.
   PubMed Web of Science ®Google Scholar
• Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology. 2004;126(6):1582–1592. doi:10.1053/j.gastro.2004.02.071
   PubMedGoogle Scholar
• Nakamura K, Honda K, Mizutani T, Akiho H, Harada N. Novel strategies for the treatment of inflammatory bowel disease: selective inhibition of cytokines and adhesion molecules. World J Gastroenterol. 2006;12(29):4628–4635. doi:10.3748/wjg.v12.i29.4628
   PubMedGoogle Scholar
• Pescovitz MD. Daclizumab: humanized monoclonal antibody to the interleukin-2 receptor. Expert Rev Clin Immunol. 2005;1(3):337–344. doi:10.1586/1744666X.1.3.337
   PubMedGoogle Scholar
• Hara S, Kiyokawa E, Iemura S, et al. The DHR1 domain of DOCK180 binds to SNX5 and regulates cation-independent mannose 6-phosphate receptor transport. Mol Biol Cell. 2008;19(9):3823–3835. doi:10.1091/mbc.e08-03-0314
   PubMedGoogle Scholar
• Lunn ML, Nassirpour R, Arrabit C, et al. A unique sorting nexin regulates trafficking of potassium channels via a PDZ domain interaction. Nat Neurosci. 2007;10(10):1249–1259. doi:10.1038/nn1953
   PubMed Web of Science ®Google Scholar
• Kurten RC, Cadena DL, Gill GN. Enhanced degradation of EGF receptors by a sorting nexin, SNX1. Science. 1996;272(5264):1008–1010. doi:10.1126/science.272.5264.1008
   PubMedGoogle Scholar
• Bergant M, Banks L. SNX17 facilitates infection with diverse papillomavirus types. J Virol. 2013;87(2):1270–1273. doi:10.1128/JVI.01991-12
   PubMedGoogle Scholar
• Aker M, Rouvinski A, Hashavia S, et al. An SNX10 mutation causes malignant osteopetrosis of infancy. J Med Genet. 2012;49(4):221–226. doi:10.1136/jmedgenet-2011-100520
   PubMed Web of Science ®Google Scholar
• Strzepa A, Szczepanik M. IL-17-expressing cells as a potential therapeutic target for treatment of immunological disorders. Pharmacol Rep. 2011;63(1):30–44. doi:10.1016/S1734-1140(11)70396-6
   PubMedGoogle Scholar
• Zhu C, Morse LR, Battaglino RA. SNX10 is required for osteoclast formation and resorption activity. J Cell Biochem. 2012;113(5):1608–1615. doi:10.1002/jcb.24029
   PubMedGoogle Scholar
• Chen Y, Wu B, Xu L, et al. A SNX10/V-ATPase pathway regulates ciliogenesis in vitro and in vivo. Cell Res. 2012;22(2):333–345. doi:10.1038/cr.2011.134
   PubMed Web of Science ®Google Scholar
• You Y, Li WZ, Zhang S, et al. SNX10 mediates alcohol-induced liver injury and steatosis by regulating the activation of chaperone-mediated autophagy. J Hepatol. 2018;69(1):129–141. doi:10.1016/j.jhep.2018.01.038
   PubMed Web of Science ®Google Scholar
• Zhou C, Wang Y, Peng J, Li C, Liu P, Shen X. SNX10 plays a critical role in MMP9 secretion via JNK-p38-ERK signaling pathway. J Cell Biochem. 2017;118(12):4664–4671. doi:10.1002/jcb.26132
   PubMedGoogle Scholar
• Zhou C, You Y, Shen W, et al. Deficiency of sorting nexin 10 prevents bone erosion in collagen-induced mouse arthritis through promoting NFATc1 degradation. Ann Rheum Dis. 2016;75(6):1211–1218. doi:10.1136/annrheumdis-2014-207134
   PubMed Web of Science ®Google Scholar
• You Y, Zhou C, Li D, et al. Sorting nexin 10 acting as a novel regulator of macrophage polarization mediates inflammatory response in experimental mouse colitis. Sci Rep-Uk. 2016;6.
   PubMedGoogle Scholar
• Neurath MF, Travis SPL. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61(11):1619–1635. doi:10.1136/gutjnl-2012-302830
   PubMed Web of Science ®Google Scholar
• Zhang S, Yang Z, Bao W, et al. SNX10 (sorting nexin 10) inhibits colorectal cancer initiation and progression by controlling autophagic degradation of SRC. Autophagy. 2020;16(4):735–749. doi:10.1080/15548627.2019.1632122
   PubMed Web of Science ®Google Scholar
• Le Y, Zhang S, Ni J, et al. Sorting nexin 10 controls mTOR activation through regulating amino-acid metabolism in colorectal cancer. Cell Death Dis. 2018;9(6):666. doi:10.1038/s41419-018-0719-2
   PubMedGoogle Scholar
• Lieberman J, Song E, Lee SK, Shankar P. Interfering with disease: opportunities and roadblocks to harnessing RNA interference. Trends Mol Med. 2003;9(9):397–403. doi:10.1016/S1471-4914(03)00143-6
   PubMed Web of Science ®Google Scholar
• Yang LB, Chu JS, Fix JA. Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int J Pharm. 2002;235(1–2):1–15. doi:10.1016/S0378-5173(02)00004-2
   PubMed Web of Science ®Google Scholar
• Sandborn MJ. Rational selection of oral 5-aminosalicylate formulations and prodrugs for the treatment of ulcerative colitis. Am J Gastroenterol. 2002;97(12):2939–2941. doi:10.1111/j.1572-0241.2002.07092.x
   PubMedGoogle Scholar
• Hanauer SB, Sparrow M. COLAL-PRED Alizyme. Curr Opin Investig Drugs. 2004;5(11):1192–1197.
   PubMedGoogle Scholar
• Mandal H, Katiyar SS, Swami R, et al. epsilon-Poly-L-Lysine/plasmid DNA nanoplexes for efficient gene delivery in vivo. Int J Pharmaceut. 2018;542(1–2):142–152. doi:10.1016/j.ijpharm.2018.03.021
   PubMedGoogle Scholar
• Martins JP, Das Neves J, de la Fuente M. The solid progress of nanomedicine. Drug Deliv Transl Res. 2020;10(3):726–729. doi:10.1007/s13346-020-00743-2
   PubMed Web of Science ®Google Scholar
• Abeer MM, Rewatkar P, Qu Z, et al. Silica nanoparticles: A promising platform for enhanced oral delivery of macromolecules. J Control Release. 2020;326:544–555. doi:10.1016/j.jconrel.2020.07.021
   PubMed Web of Science ®Google Scholar
• Steed KP, Hooper G, Monti N, Benedetti MS, Fornasini G, Wilding IR. The use of pharmacoscintigraphy to focus the development strategy for a novel 5-ASA colon targeting system (“TIME CLOCK (R)” system). J Control Release. 1997;49(2–3):115–122. doi:10.1016/S0168-3659(97)00062-X
   Web of Science ®Google Scholar
• Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V. PLGA-based nanoparticles: an overview of biomedical applications. J Control Release. 2012;161(2):505–522. doi:10.1016/j.jconrel.2012.01.043
   PubMed Web of Science ®Google Scholar
• Elzatahry AA, Eldin MSM, Soliman EA, Hassan EA. Evaluation of alginate-chitosan bioadhesive beads as a drug delivery system for the controlled release of theophylline. J Appl Polym Sci. 2009;111(5):2452–2459. doi:10.1002/app.29221
   Google Scholar
• Pujara N, Wong KY, Qu Z, et al. Oral delivery of beta-lactoglobulin-nanosphere-encapsulated resveratrol alleviates inflammation in winnie mice with spontaneous ulcerative colitis. Mol Pharm. 2020. doi:10.1021/acs.molpharmaceut.0c00048
   PubMedGoogle Scholar
• Qu Z, Wong KY, Moniruzzaman M, et al. One-pot synthesis of ph-responsive eudragit-mesoporous silica nanocomposites enable colonic delivery of glucocorticoids for the treatment of inflammatory bowel disease. Adv Ther-Germany. 2020;2000165. doi:10.1002/adtp.202000165
   Google Scholar
• Mahajan N, Sakarkar D, Manmode A, Pathak V, Ingole R, Dewade D. Biodegradable nanoparticles for targeted delivery in treatment of ulcerative colitis. Adv Sci Lett. 2011;4(2):349–356. doi:10.1166/asl.2011.1247
   Google Scholar
• Hacker H, Redecke V, Blagoev B, et al. Specificity in Toll-like receptor signalling through distinct effector functions of TRAF3 and TRAF6. Nature. 2006;439(7073):204–207. doi:10.1038/nature04369
   PubMedGoogle Scholar
• Sanchez-Munoz F, Fonseca-Camarillo G, Villeda-Ramirez MA, et al. Transcript levels of toll-like receptors 5, 8 and 9 correlate with inflammatory activity in ulcerative colitis. BMC Gastroenterol. 2011;11:138. doi:10.1186/1471-230X-11-138
   PubMed Web of Science ®Google Scholar
• De Jager PL, Franchimont D, Waliszewska A, et al. The role of the Toll receptor pathway in susceptibility to inflammatory bowel diseases. Genes Immun. 2007;8(5):387–397. doi:10.1038/sj.gene.6364398
   PubMedGoogle Scholar
• Tan Y, Zou KF, Qian W, Chen S, Hou XH. Expression and implication of toll-like receptors TLR2, TLR4 and TLR9 in colonic mucosa of patients with ulcerative colitis. J Huazhong Univ Sci Technolog Med Sci. 2014;34(5):785–790. doi:10.1007/s11596-014-1353-6
   PubMedGoogle Scholar
• Fan Y, Liu B. Expression of Toll-like receptors in the mucosa of patients with ulcerative colitis. Exp Ther Med. 2015;9(4):1455–1459. doi:10.3892/etm.2015.2258
   PubMedGoogle Scholar
• Frolova L, Drastich P, Rossmann P, Klimesova K, Tlaskalova-Hogenova H. Expression of Toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples of patients with inflammatory bowel diseases: upregulated expression of TLR2 in terminal ileum of patients with ulcerative colitis. J Histochem Cytochem. 2008;56(3):267–274. doi:10.1369/jhc.7A7303.2007
   PubMed Web of Science ®Google Scholar
• Erridge C, Duncan SH, Bereswill S, Heimesaat MM. The induction of colitis and ileitis in mice is associated with marked increases in intestinal concentrations of stimulants of TLRs 2, 4, and 5. PLoS One. 2010;5:2. doi:10.1371/journal.pone.0009125
   Google Scholar
• Zhang XQ, Dahle CE, Baman NK, Rich N, Weiner GJ, Salem AK. Potent antigen-specific immune responses stimulated by codelivery of CpG ODN and antigens in degradable microparticles. J Immunother. 2007;30(5):469–478. doi:10.1097/CJI.0b013e31802fd8c6
   PubMed Web of Science ®Google Scholar
• Siegmund B, Fantuzzi G, Rieder F, et al. Neutralization of interleukin-18 reduces severity in murine colitis and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol. 2001;281(4):R1264–73. doi:10.1152/ajpregu.2001.281.4.R1264
   PubMed Web of Science ®Google Scholar
• Levin A, Shibolet O. Toll-like receptors in inflammatory bowel disease-stepping into uncharted territory. World J Gastroentero. 2008;14(33):5149–5153. doi:10.3748/wjg.14.5149
   PubMedGoogle Scholar
• Rakoff-Nahoum S, Hao L, Medzhitov R. Role of toll-like receptors in spontaneous commensal-dependent colitis. Immunity. 2006;25(2):319–329. doi:10.1016/j.immuni.2006.06.010
   PubMed Web of Science ®Google Scholar
• Heimesaat MM, Fischer A, Siegmund B, et al. Shift towards pro-inflammatory intestinal bacteria aggravates acute murine colitis via Toll-like receptors 2 and 4. PLoS One. 2007;2(7):e662. doi:10.1371/journal.pone.0000662
   PubMed Web of Science ®Google Scholar
• Matsuguchi T, Takagi K, Musikacharoen T, Yoshikai Y. Gene expressions of lipopolysaccharide receptors, toll-like receptors 2 and 4, are differently regulated in mouse T lymphocytes. Blood. 2000;95(4):1378–1385. doi:10.1182/blood.V95.4.1378.004k08_1378_1385
   PubMedGoogle Scholar
• Coskun M, Steenholdt C, de Boer NK, Nielsen OH. Pharmacology and optimization of thiopurines and methotrexate in inflammatory bowel disease. Clin Pharmacokinet. 2016;55(3):257–274. doi:10.1007/s40262-015-0316-9
   PubMed Web of Science ®Google Scholar
• Nielsen OH, Coskun M, Steenholdt C, Rogler G. The role and advances of immunomodulator therapy for inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2015;9(2):177–189. doi:10.1586/17474124.2014.945914
   PubMed Web of Science ®Google Scholar
• Olesen CM, Coskun M, Peyrin-Biroulet L, Nielsen OH. Mechanisms behind efficacy of tumor necrosis factor inhibitors in inflammatory bowel diseases. Pharmacol Ther. 2016;159:110–119. doi:10.1016/j.pharmthera.2016.01.001
   PubMed Web of Science ®Google Scholar
• Torres J, Boyapati RK, Kennedy NA, Louis E, Colombel JF, Satsangi J. Systematic review of effects of withdrawal of immunomodulators or biologic agents from patients with inflammatory bowel disease. Gastroenterology. 2015;149(7):1716–1730. doi:10.1053/j.gastro.2015.08.055
   PubMed Web of Science ®Google Scholar
• Check E. A crucial test. Nat Med. 2005;11(3):243–244. doi:10.1038/nm0305-243
   PubMedGoogle Scholar